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Summary Nine patients with progressive, metastatic disease from primary carcinoma of the colon were
entered into a phase I/II study using continuous intravenous infusions of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and high dose melphalan (120mgm-2). GM-CSF was given alone to six
patients during the first part of the study to determine a dose that would produce a peripheral leucocyte count
(WCC) > 50 x I09 1'- and was initially given at 3 glg kg-' day-' and escalated to 10 jig kg-' day-' after 10
days. The infusion was discontinued when the WCC exceeded 50 x 1091-l and after a gap of one week,
melphalan was given over 30 min. GM-CSF was recommenced 8 h later and was continued until the
neutrophil count had exceeded 0.5 x 1091-l for > I week. One patient achieved a WCC > 50 x 1091- with
GM-CSF 3jlg kg-' day-', but the other five who entered this phase of the study required dose escalation to
10 xLg kg-'. No toxicity attributed to GM-CSF was seen. After melphalan, the median times to severe
neutropenia (<0.5 x109 1-) and thrombocytopenia (<20 x1091-') were 6 and 9 days respectively. The
median durations of neutropenia and. thrombocytopenia were 14 and 10 days respectively. All patients
required intensive support with a median duration of inpatient stay of 24 days. There was one treatment
related death due to renal failure. One complete and two partial remissions (33% response rate) were seen but
these were of short duration (median of 10 weeks). This study demonstrates that GM-CSF given by
continuous intravenous infusion produces significant increments of peripheral granulocyte counts at 3 and
10 fig kg-' day-' and is not associated with any toxicity. The duration of neutropenia and thrombocytopenia
induced by high-dose melphalan appears to be reduced by the subsequent administration ofGM-CSF to times
which are at least as short as have been reported in historical series which have used autologous bone marrow
rescue.
Carcinoma of the colon is one of the commonest causes of
death from malignancy in the Western world. Although re-
cent improvements in therapy have led to increased survival
for a variety of solid tumours, the outlook for patients with
colo-rectal cancer has not altered for at least 20 years. The
response rate to chemotherapy is disappointing and even the
most widely used cytotoxic agent, 5-fluorouracil, induces
remissions in only 15-25% of patients (Davis, 1982). Clear-
ly, new approaches are needed if improvements are to be
made in the treatment of this disease.
There is increasing interest in the results of in vitro and
in vivo experiments which have demonstrated steep dose-
response relationships for chemotherapy in a variety of tu-
mours (Frei, 1979; Frei & Canellos, 1980; Henderson et al.,
1988). In transplantable animal tumours there is a very
strong relationship between the dose of cytotoxic delivered
and the capacity to cure, with dose reductions of 20% being
associated with a fall of the cure rate of up to 50% (de Vita,
1986). Similar information is not as clearly obtainable from
published studies in humans, although analyses (predomin-
antly retrospective) comparing the amount of chemotherapy
delivered and the response rate have suggested that optimal
results are obtained with higher doses of drugs (Bonadonna
& Valagussa, 1981; O'Bryan et al., 1977). Unfortunately
many cytotoxic agents have a low therapeutic index and
serious toxicity (most importantly myelosuppression) is
associated with high dose chemotherapy. In order to reduce
the duration and severity of myelosuppression and to allow
high-dose treatment to be given more safely, autologous
bone-marrow rescue (ABMR) has been increasingly used in
patients with a variety of malignancies. A recent report of 20
patients with metastatic colon cancer who were given mel-
phalan 180 mg m2 followed by ABMR showed a response
rate of 45% (higher than with conventional chemotherapy)
with acceptable toxicity (Leff et al., 1986). Unfortunately,
bone marrow harvesting is time consuming, expensive and
necessitates the patient having a general anaesthetic.
We have carried out a phase I study with recombinant
human granulocyte-macrophage colony stimulating factor
(GM-CSF) and shown that when it was given as daily intra-
venous half-hour infusions, significant rises in leucocyte
counts were obtained, but only at high dose levels
(> 30 gg kg-' day-') which were associated with consider-
able toxicity (Steward et al., 1989). Several trials have shown
that haemopoietic growth factors can reduce the mye-
lotoxicity of chemotherapy (Bronchud et al., 1987; Antman
et al., 1988; Morstyn et al., 1988) and we therefore decided to
combine high-dose melphalan with GM-CSF for patients
with metastatic colorectal carcinoma in the hope that we
could obtain similar response rates to those of Leff et al.
(1986), but without the need for ABMR. The dose of mel-
phalan was chosen as 120 mg m-2 because ofexperience from
the Royal Marsden Hospital which has shown that patients
can survive after this amount of chemotherapy without the
need for ABMR, albeit with prolonged periods of myelosup-
pression (Selby et al., 1987). Haemopoietic colony stimu-
lating factors have short serum half-lives and the responding
progenitor cells require continual exposure to these molecules
for survival (Burgess et al., 1987). In the hope that a greater
biological effect could be obtained, GM-CSF was therefore
given as a continuous intravenous infusion rather than by
bolus injection in this study. To determine the dose of
growth factor that would be given after melphalan, an initial
phase I part of the trial with GM-CSF alone was included.
Materials and methods
Patients
Adult patients (age > 18 years) with measurable, progressive
metastatic lesions from a primary carcinoma of the colon
were eligible to enter this study. A Karnofsky performance
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status > 70 and normal renal function (creatinine clearance
> 50 ml min-') were the other entry criteria. All patients
gave written informed consent.
Study design
During the initial part of the study, patients received GM-
CSF (E. coli, non-glycosylated, Schering-Plough/Sandoz)
alone as a continuous intravenous infusion using an ambu-
latory pump (CADD-1 model, Pharmacia) and central ven-
ous line. The end-point for this phase of the trial was the
achievement of a total white cell count (WCC)
> 50 x 109 1-'. The starting dose of GM-CSF was 3fg kg-'
day-' but this was escalated to 10fig kg-' day-' if, after 10
days of the infusion, the target white count had not been
reached. GM-CSF was discontinued when the WCC
> 50 x 1091-' and, 7 days later, the patients were given
melphalan 120 mgm-2 as a short intravenous infusion with
hydration and frusemide-induced diuresis. Eight hours after
administration of melphalan, GM-CSF was recommenced as
a continuous intravenous infusion using the dose for each
individual patient which had caused the target rise of the
WCC. GM-CSF was continued until one week beyond
recovery of a neutrophil count > 0.5 x 109 1-'.
Evaluation ofresponse and toxicity
Toxicity was assessed by WHO criteria. Before entry to the
study all patients had evaluable disease as assessed by radio-
logical or ultrasound investigation. The response to treatment
was determined 6-7 weeks after melphalan administration by
repetition of all previously abnormal investigations and was
graded according to standard UICC criteria. The duration of
response was measured from the date of assessment and
survival was calculated from the day of melphalan admini-
stration.
Pharmacokinetics of GM-CSF
Serial specimens of sera were taken from patients after com-
mencing the administration of GM-CSF on the first day of
the initial phase of the study and GM-CSF concentrations
were measured by an Elisa radioimmunoassay (with a sen-
sitivity of 0.3 ng ml-') in the laboratories of Schering-Plough
(New Jersey, USA).
Results
Patients
Nine patients (characteristics shown in Table I) with metas-
tatic colon cancer were treated in this study. The first six
patients received GM-CSF alone in the first phase of the
study and subsequently received melphalan followed by GM-
CSF. The last three patients to be recruited only took part in
the second phase of the trial, receiving no growth factor
before melphalan. All the patients made a complete haema-
tological recovery after melphalan administration and are
evaluable for toxicity. One patient died on day 26 after
melphalan and is not evaluable for response.
Response to GM-CSF
The results of the phase I part of the study revealed a rapid
rise of the white cell count (WCC) after commencing an
infusion of GM-CSF. One patient achieved a count
>50x l091-' after 10 days of GM-CSF at a dose of
3 sg kg-' day-' whereas the other five patients required an
escalation to 10jug kg-' day-' for a further 1-3 days. How-
ever, as can be seen from the profile of the median WCC for
the total patient group (Figure 1), it is likely that all patients
would have achieved the target count at 3fig kg-' after 12
days had the study design not stipulated a dose escalation at
day 10. Differential blood counts showed the predominant
Table I Patient characteristics
Characteristic Number
Median age (range) 47 (33-66)
Gender (male:female) 5:4
Performance status, median (range) 80 (70-90)
Prior chemotherapy 2
Evaluable for toxicity 9
Evaluable for response 8
Sites measurable disease
liver metastases 3
retroperitoneal lymph nodes 5
bowel recurrence 5
pulmonary metastases 1
skin I
Bone marrow involved 0
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Figure 1 Profile of median total leucocyte count ( ), neut-
rophil count ( m ), and eosinophil count ( O ) for patients
receiving continuous intravenous infusion of GM-CSF at
3fg kg-' day-' for 10 days followed by escalation of the dose to
10 lgkg-' day-'.
rise in the WCC to be due to an increase of neutrophil
polymorphs but a small increase of eosinophils also occurred
in parallel. The striking difference between the effects of
GM-CSF given by continuous infusion or daily short injec-
tions is illustrated in Figure 2, which shows the haema-
tological responses of one patient who entered both this
study and a previous trial (Steward et al., 1989) of GM-CSF
alone. After the experience with these initial six patients, a
decision was taken that the optimal dose of GM-CSF after
melphalan was 10 g kg-' day-' and the final three patients
were not entered into the first phase of the study. Encourag-
ingly, although the GM-CSF produced significantly greater
rises of the WCC when given by a continuous infusion as
compared with bolus administration, no toxicity was seen
when the former route was used.
Response to high-dose melphalan (HDM)
Assessment of anti-tumour response in the eight evaluable
patients (Table II) was made between weeks 6 and 7 after
administration of HDM. One complete and two partial re-
sponses (33% overall response rate) were observed. Unfor-
tunately, the response duration was short, lasting only 2-3
months.
Pharmacokinetics ofGM-CSF
The different effects on the blood count of the continuous
infusion of GM-CSF as compared with a previous study
using intermittent short infusions may relate to the pharma-
cokinetics of this growth factor. For this reason, serial serum
specimens were taken from three patients over the first 24 h
of the infusion for measurement of GM-CSF levels. These
showed a steady rise to a serum level > 1 ng ml-' (the con-
centration required in vitro to produce >90% of maximal
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Figure 2 Profile of total leucocyte count in patient receiving
GM-CSF given by daily intravenous half-hour bolus injections
) at a dose of I0Oig kg-' day-' and, 4 months later, as a
continuous infusion (- *-) at a dose of 3 ;Lg kg-' day-'. The
triphasic increase of peripheral leucocyte count seen after the
administration of GM-CSF is illustrated with an initial early rise
due to demargination of cells, a subsequent plateau phase and a
final phase of rapid rise due to the appearance of leucocytes
produced as a result of proliferation of bone marrow progenitor
cells. The two curves show the superiority of continuous infusions
over bolus injections with the former route producing a
significantly higher rise of the white blood cell count even though
the dose of GM-CSF was lower.
cell proliferation) (Metcalf, 1984) within 3 h of commencing
the infusion. Figure 3 shows the serum GM-CSF levels and
compares these with those seen after short intravenous
administration (measured during previous study (Steward et
al., 1989)).
Toxicity
All nine patients were evaluable for toxicity. The main target
organs for the toxicity of HDM were the bone marrow and
the gastrointestinal tract (summarised in Table III). Details
of the durations of these toxicities for the total patient group
are shown in Table IV. The median time to reach a neutro-
phil count < 0.5 x I0 1-' was 6 days with a narrow range
between 5-7 days. The median time to reach a platelet count
< 20 x 109 1' was 9 days with a wider range of 7-12 days.
The median durations of neutropenia ( < 0.5 x 1091-) and
thrombocytopenia (<20 x 1091-) were 14 days (range
10-22 days) and 10 days (range 5-24 days) respectively. All
patients received GM-CSF until 1 week after recovery of the
granulocyte count (<0.5 x 1091') and to achieve this,
administration continued for a median of 27 days (range
15-35 days). After the first six patients had been entered into
the study, concern was expressed that pre-treatment with
GM-CSF could cause myeloid progenitors to remain in cell
cycle such that subsequent administration of melphalan
would be more cytotoxic for these cells. The final three
patients therefore did not receive GM-CSF before melphalan.
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Figure 3 a, Profile of mean serum GM-CSF levels over 24 h
after 30 min intravenous infusion: at 10 yg kg-' ( ), 2 pa-
tients, and at 60 lAg kg-} (- ), 2 patients. b, Profile of mean
serum GM-CSF levels over 24 h during continuous intravenous
infusion (3gtg kg-'), 3 patients. Measurement was by radio-
immunoassay (carried out in the laboratories of Schering-Plough,
New Jersey, USA).
Table III Toxicity (WHO grade) after melphalan
Grade/number pts
I 11 III IV
a) Haematological Haemoglobin 2 5 1 1
Leucocyte 9
Granulocyte 9
Platelet 9
Haemorrhage I I
b) Gastrointestinal Nausea/vomiting 5 1
Diarrhoea 4 1
Oral mucositis 4 3
c) Fever (during leucopenia) 9
d) Infection 3 1
Table II Response assessment after high-dose melphalan
Response Number Site response Duration response Current status
Complete I Retroperitoneal 86 days Alive 160 days
lymph nodes
Partial 2 Liver & bowel 97 days Died 300 days
Retroperitoneal 68 days Died 207 days
lymph nodes
Stable disease 3 Liver 80 days Died 227 days
Retroperitoneal 36 days Died 113 days
lymph nodes,-&
bowel
Retroperitoneal 38 days Died 119 days
lymph nodes &
bowel
Progressive 2 - Died 74 days
Died 48 days752 W.P. STEWARD et al.
Table IV Haematological toxicity
Median number days
(range) from administration
ofmelphalan to reach each
haematological parameter
Median number days
(range) ofduration
ofeach haematological
parameter
Total leucocyte
count <1.0x 1091-' 6 (5-7) 14 (10-23)
Granulocyte count
< 1.0 x 109 1-' 5 (5-6) 15 (10-22)
Granulocyte count
< 0.5 x 109 1-' 6 (5-7) 14 (10-22)
Platelet count
< 100 x 109 1- 6 (4-9) 17 (12-46)
Platelet count
-50x '091-1 7(6-11) 15(9-33)
Platelet count
<20x 1091- 9(7-12) 10(5-24)
Although the median duration of neutropenia after HDM
was 2 days shorter for the latter group (compared with the
patients who received GM-CSF prior to HDM), the number
of patients is too small to make statistical comparisons or
draw firm conclusions as to whether exposure to myeloid
growth factors prior to chemotherapy prolongs myelotox-
icity.
Six patients experienced some degree of nausea or vomi-
ting although these symptoms resolved within 24-48 h after
administration of HDM. Diarrhoea occurred at some stage
in five patients, always during periods of myelosuppression
when the patients were being treated with broad-spectrum
antibiotics. Clostridium difficile toxin was never demonstra-
ted. All our patients developed complete alopecia.
Infections
All patients developed fever during their period of neutro-
penia. No prophylactic antibiotic or antifungal agents were
given. Broad-spectrum antibiotics were commenced immed-
iately a fever was documented and were continued until
resolution of the fever and recovery of a granulocyte count
> 0.5 x I0 1 '. Although blood and other cultures were re-
peatedly taken, no organisms were isolated during any of the
periods of neutropenia.
Seven patients suffered from moderate oral mucostis and
in three an infection with herpes simplex virus (together with
Candida albicans in one) was documented.
Supportive care
All but one patient left the hospital within 24-48 h after
administration of HDM. Peripheral counts were checked
daily in the outpatients clinic and all patients were readmit-
ted within 7 days when neutropenic. Patients remained in
hospital for a median period of 24 days (range 18-46 days).
Red cell transfusions were given in order to keep the haemo-
globin level above 10g dl-' and platelets were administered
when their count fell below 20 x 109 1'. A median of 7 units
of packed red cells (range 4-20) and a median of 31 units of
platelets (range 8-72) were admininstered to each patient.
All patients received broad-spectrum antibiotics for episodes
of fever during the period of neutropenia for a median of 17
days (range 8-21 days).
Specific complications
One treatment related death occurred in a 47-year-old man,
26 days after HDM. He developed Poliguria on day 13 while
receiving broad spectrum antibiotic and antifungal agents
(Piperacillin, Vancomycin, Netilmycin, Amphothericin B).
Despite the discontinuation of these drugs 24 h later (the
patient had almost made a full haematological recovery at
this time and was apyrexial), and support with fluids and
diuretics, the renal function deteriorated steadily. No focus of
infection was found and an ultrasound examination ruled out
any post-renal obstruction - both kidneys were somewhat
enlarged, suggesting an intrinsic cause for this renal failure.
The patient died in uraemic coma 13 days after the onset of
oliguria. No dialysis was performed. Drug levels for both
vancomycin and netilmycin were within therapeutic limits on
the days preceding the renal failure.
A 66-year-old lady, who experienced a partial response,
developed a haemolytic anaemia with a sudden drop in
hemoglobin level from 9.2 gdl-' on day 10 to 6.5 gdl-' on
day 11. This was accompanied by a rapid rise in both serum
LDH and bilirubin levels. A direct Coombs test was positive
at this time, having been negative at the time of entry to the
study. This haemolytic anaemia caused serious transfusion
problems, 15 units of packed cells being given with little
effect in terms of increasing the haemoglobin level. By day 31
a full recovery of the peripheral count had occurred.
The effects ofrGM-CSF on bone marrow cultures
Bone marrow examination was performed in two patients
after complete restoration of the peripheral counts. The mor-
phology of both these marrows demonstrated normal to
increased cellularity and normal trilineage haemopoiesis.
However, the incidence of haemopoietic progenitor cells
assayed on semi-solid media (Testa, 1985) showed markedly
reduced numbers of myeloid and erythroid progenitors
(Table V). In in vitro long-term bone marrow culture (Gart-
ner & Kaplan, 1980), the generation of myeloid progenitors
was subnormal (as compared with marrow from donors who
had not received chemotherapy) and ceased after four weeks.
in culture (Table VI). These results suggested that there
would be a high risk of prolonged marrow depression if a
second course of chemotherapy was given and so no patient
was given more than one course of melphalan.
A post mortem examination was performed on a 33-year-
old man who died ofprogressive disease 48 days after HDM.
This demonstrated the presence of erythroid and numerous
myeloid islands in the spleen.
Table V Results of progenitor cell assay (CFC-GEMM) on methyl
cellulose (expressed as progenitors per 105 nucleated cells) for two
patients after one course of HDM
Progenitor cell
Multipotential Myeloid/macrophage Erythroid
Patient 1 0 2 6
Patient 2 0 3 4
Table VI Number of progenitor cells (GM-CFC) generated in long-
term bone marrow culture (expressed as GM-CFC per flask) for two
patients after one course of HDM
Weeks in culture
1 2 3 4 5
Patient 1 420 180 60 18 0
Patient 2 240 110 20 0 0
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Discussion
This study has investigated two aspects of the clinical use of
the haemopoietic growth factor, GM-CSF. The first phase of
the trial demonstrated that continuous intravenous infusions
of GM-CSF at doses of 3 and 10 Lg kg-' day-' produced
significant increases of the peripheral leucocyte count (pre-
dominantly neutrophils) without any associated toxicity. This
is in marked contrast to our previous experience using daily
half-hour intravenous infusions of GM-CSF (Steward et al.,
1989) when only minimal increments of the neutrophil counts
occurred at these dose levels and serious toxicity was seen.
Both routes of administration caused a triphasic increase in
the peripheral leucocyte count (Figure 2). Over the first 4
days an increase occurred which was attributed to the demar-
gination of pre-existing mature cells, and was followed by a
plateau phase lasting 3-4 days. A more rapid and marked
increase occurred after day 8 and was attributed to the
appearance of leucocytes from bone marrow progenitor cells
induced to proliferate by GM-CSF.
The results of serial measurements of serum GM-CSF
concentrations gave a probable explanation for the different
effects seen with the two schedulings of administration. Even
at 3 tLg kg-' day-', serum levels rapidly rose to remain above
I ng ml-' when continuous infusions were used, but this
concentration was only exceeded for a maximum of 12 h
after 30 min infusions at all dose levels. The survival of
myeloid progenitor cells in bone marrow cultures is depen-
dent on continuous exposure to haemopoietic growth factors
(Burgess et al., 1987) and the rate of their proliferation is
related to the concentration of these factors in the medium.
It has been demonstrated in vitro that >90% maximal cell
proliferation only occurs when GM-CSF concentrations ex-
ceed 1 ng ml-' (Metcalf, 1984). The results of our study
suggest that the in vitro effects of GM-CSF on myeloid
progenitor cells are similar to the effects seen in vivo in
humans as continuous effective serum levels caused
significantly greater increments of circulating mature granu-
locytes than did fluctuating serum levels. It was particularly
encouraging that the continuous infusions of GM-CSF could
produce greater increments of leucocyte counts than were
seen with daily short infusions so that the dosage did not
have to be escalated to levels which produced toxicity.
Significantly greater white count increments have also been
produced by subcutaneous administration of GM-CSF as
compared with short intravenous injections (Lieschke et al.,
1989) and again this can be attributed to the more prolonged
effective serum levels of growth factor seen after this route of
administration.
The second phase of this study investigated the role of
GM-CSF in reducing the haematological toxicity of high
dose chemotherapy. Single agent melphalan was chosen
because of its predictable pharmacokinetics with rapid serum
elimination (Ardiet et al., 1986) and because of the demon-
stration that at doses > 100mgm2, responses could be
induced in a wide range of advanced haematological and
solid tumours (McElwain et al., 1979; Lazarus et al., 1983;
Corringham et al., 1983; Cornbleet et al., 1983; Hartmann et
al., 1986). Haematological toxicity of melphalan at doses
> 100mg m-2 has been reported in the literature
predominantly using autologous bone marrow rescue
(ABMR). There seems little doubt from the experience at the
Royal Marsden Hospital that ABMR significantly reduces
the periods of neutropenia and thrombocytopenia (McElwain
et al., 1979), and time to recovery of a normal peripheral
count appears to relate to the number of nucleated cells
which are re-infused into the patient (Ekert et al., 1982).
Although several of these studies have used doses of mel-
phalan > 120 mg m2, the majority have employed different
doses in sequential patient groups. All reported no significant
difference in the degree or duration of myelosuppression as
the dose of melphalan increased and it would therefore seem
reasonable to compare ours with other series. The median
durations of neutropenia (<0.5 x I091') and thrombo-
cytopenia (< 20 x 109 ') were 14-28 days and 20-26 days
respectively in these studies (Hartmann et al., 1986; Lazarus
et al., 1983; Corringham et al., 1983). In our study using
GM-CSF, the median duration of neutropenia of 14 days is a
similar duration to that seen with ABMR, and the median
duration of thrombocytopenia of 10 days may be shorter. A
randomised study would be necessary to confirm the relative
benefits of the use of haemopoietic growth factors and
ABMR following HDM. Effects of GM-CSF on platelet
production have been seen previously in patients with myelo-
dysplasia (Vadhan-Raj et al., 1988) and after chemotherapy
(Antman et al., 1988) and could be anticipated from in vitro
bone marrow culture experiments (Metcalf, 1985).
Interestingly, the median period between administration of
melphalan and the onset of granulocytopaenia and thrombo-
cytopenia (6 and 9 days respectively) seen in our study was
virtually identical to all other series. In two trials using
granulocyte colony-stimulating factor (G-CSF) after chemo-
therapy, the time of onset of nadir leucocyte counts was
earlier when growth factor was employed as compared with
control courses (Bronchud et al., 1987, 1989). There is no
obvious explanation for the apparent difference between G-
and GM-CSF in terms of their altering the timing of the
neutrophil nadir after chemotherapy.
As in other series employing high-dose melphalan, non-
haematological toxicity, predominantly related to the gastro-
intestinal tract, occurred. This was generally not severe.
Unfortunately there was one treatment-related death from
renal failure which was attributed to the administration of a
combination of nephrotoxic antibiotics. Acute renal failure
has been reported with GM-CSF (Brandt et al., 1988) but it
was reversible on discontinuing this agent and only occurred
at high dose levels (32 tLg kg-' day-). It would seem unlikely
that GM-CSF was the cause of renal failure in our patient as
the dose used was significantly lower and there was no
reversal on discontinuing the infusion.
A final aim of this study was to further investigate the
activity of melphalan in advanced carcinoma of the colon.
The response rate of 33% is similar to that seen in other
series, but, unfortunately, as in these series, the durations of
response and survival were short. An alternative approach is
needed before this becomes a useful treatment for future
similar patients. One such approach may be to give further
courses of melphalan (perhaps at a higher dosage), but be-
fore this was attempted it would be sensible to cryopreserve
bone marrow before the first course is given. This would
allow bone marrow rescue to be given after subsequent cycles
if cumulative toxicity prevented recovery using growth factor
alone (a possibility suggested by in vitro assays performed in
two of our patients). The prompt haematological recovery
induced by GM-CSF after one course of melphalan is en-
couraging and suggests that this is a useful alternative to
ABMR for at least a single cycle of high-dose chemotherapy.
A further approach in future studies where multiple cycles
are attempted could be to combine a colony stimulating
factor with an aliquot of harvested bone marrow. By this
means it may be possible to obtain early engraftment without
the need for 2-5 x 108 nucleated cells kg-' (the number of
cells necessary for optimal rescue). A variety of malignant
diseases have shown encouraging response rates to high-dose
melphalan but, as with our study, only one or, at most, two
courses have been given. Any approach which would allow
this therapy to be given as repeated cycles could have con-
siderable potential benefit.
This study has demonstrated that, when given by the
intravenous route, continuous infusions of GM-CSF are
significantly more effective than intermittent short infusions
in terms of inducing a neutrophil increment. It is hoped the
use of GM-CSF or other haemopoietic growth factors will
enable the safer use of high-dose chemotherapy in future
studies and if, as is anticipated, a dose-response relationship
exists for cytotoxic agents used in patients with responsive
neoplasms, improvements in the results of treatment will
follow.754 W.P. STEWARD et al.
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